Home › Compare › TNJIF vs ABBV
TNJIF yields 5.08% · ABBV yields 3.06%● Live data
📍 TNJIF pulled ahead of the other in Year 2
Combined, TNJIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TNJIF + ABBV for your $10,000?
Tianjin Capital Environmental Protection Group Company Limited, together with its subsidiaries, engages in the sewage treatment and construction of the sewage treatment plants in the People's Republic of China. It operates through Sewage Water Processing and Water Plant Facilities Construction; Recycled Water and Pipeline Connection; Heating and Cooling Supply and Related Facilities Construction; Tap Water and Water Plant Facilities Construction; Sale of Environmental Protection Equipment; and All Other segments. The company offers municipal sewage treatment, and water supply and recycling services, as well as sludge treatment, photovoltaic power generation, transformation of achievements in technology research, etc.; and involved in hazardous wastes business. It also provides toll collection services; environment governance, technical consulting services, etc.; technical consulting for water recycling business; energy saving and research, consulting and transfer, and property management services; and industrial solid waste incineration and disposal, and general waste recycling services, as well as invests in construction projects; and manufactures and sells new building materials. The company was founded in 1993 and is based in Tianjin, the People's Republic of China. Tianjin Capital Environmental Protection Group Company Limited is a subsidiary of Tianjin Municipal Investment Company Limited.
Full TNJIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.